{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Osimertinib + Chemotherapy Improves Survival in Advanced NSCLC

Activity Steps


Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify the combination therapy that was used in the Phase III FLAURA2 trial.
  2. Compare results from the Phase III FLAURA2 trial for patients who received osimertinib monotherapy with the results for patients who received osimertinib plus chemotherapy.
Price: $10.00


  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: OT0424
Published: April 2024
Expires: 3/31/2026
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Categories: Hematology , Oncology
Specialties: Hematology, Oncology